Background
Rituximab-chemotherapy was the frontline standard for follicular lymphoma (FL). GALLIUM compared obinutuzumab (glycoengineered type II anti-CD20 with enhanced ADCC) versus rituximab, each combined with chemotherapy (CHOP, CVP, or bendamustine) and followed by maintenance, in previously untreated FL.
Interventions and follow up
Arm A: Obinutuzumab + chemotherapy (CHOP, CVP, or bendamustine) induction, then obinutuzumab maintenance every 2 months x2 years
Arm B: Rituximab + chemotherapy induction, then rituximab maintenance every 2 months x2 years
Population: N=1202, untreated FL (grade 1-3a)
Primary endpoint: investigator-assessed PFS
Median follow-up: 34.5 months
Arm B: Rituximab + chemotherapy induction, then rituximab maintenance every 2 months x2 years
Population: N=1202, untreated FL (grade 1-3a)
Primary endpoint: investigator-assessed PFS
Median follow-up: 34.5 months
Results
3-yr PFS: 80.0% vs 73.3% (HR 0.66, 95% CI 0.51–0.85, P=.001)
OS: no significant difference at primary analysis
5-yr update: PFS benefit maintained (HR 0.70)
Subgroups: benefit consistent across chemotherapy backbones
OS: no significant difference at primary analysis
5-yr update: PFS benefit maintained (HR 0.70)
Subgroups: benefit consistent across chemotherapy backbones
Adverse events
Overall: Grade 3-5 AEs 74.6% vs 67.8%; fatal AEs 4.0% vs 3.4% (higher with bendamustine backbone)
Hematologic: neutropenia (Grade 3-4) ~48% vs ~40%
Infusion/Infection: Grade 3-4 infusion reactions 12% vs 5%; infections 17% vs 12%
Other: second malignancies 4.5% vs 3.1%
Hematologic: neutropenia (Grade 3-4) ~48% vs ~40%
Infusion/Infection: Grade 3-4 infusion reactions 12% vs 5%; infections 17% vs 12%
Other: second malignancies 4.5% vs 3.1%
Conclusions
Obinutuzumab-chemotherapy significantly improved PFS over rituximab-chemotherapy in untreated FL, but with greater toxicity and no OS benefit, raising questions about the optimal frontline anti-CD20 backbone.
Key Limitations
No OS benefit; higher toxicity including more fatal AEs (notably bendamustine arm); modest absolute PFS gain at cost of increased infusion reactions, neutropenia and infections; cost of obinutuzumab; relevance amid evolving chemo-free FL options.
Clinical Context
FDA approved obinutuzumab with chemotherapy for previously untreated FL in 2017; EMA followed. ESMO/ASCO guidance lists both obinutuzumab- and rituximab-based immunochemotherapy as acceptable frontline FL options, with backbone and antibody choice individualized by toxicity, comorbidity, and patient preference.